{"Clinical Trial ID": "NCT00723125", "Intervention": ["INTERVENTION 1:", "Cohort 1", "Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes week x 12 weeks with carboplatin at AUC 6 over 30 minutes IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2 weeks x 4 cycles Final Surgery Avastin 10 mg/kg IV over 30-60 minutes q2 weeks x 34 weeks", "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes x 12 weeks with carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 (in Cohort 2, omit the dose of Avastin over week 10)", "INTERVENTION 2:", "Cohort 2", "Abraxane 100 mg/m2 IV over 30 minutes -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes x 12 weeks with carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 (in Cohort 2, omit the Avastin dose over week 10) Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2 weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2 weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2 weeks x 42 weeks", "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes x 12 weeks with carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 (in Cohort 2, omit the dose of Avastin over week 10)"], "Eligibility": ["\u2022 Eligibility criteria", "\u2022 Inclusion criteria:", "Adenocarcinoma of histologically documented breast", "ANC > 1000 cells", "Women; age > 18", "- Zubrod PS 0-1", "\u2014 Blisters > 100 000", "Stage IIA-IIIB disease", "Total bilirubin < 1.5 LSN", "No sign of metastatic disease", "Serum creatinine < 1.5 gm/dl", "No previous systemic treatment for breast cancer or Creat Cl cancer > 30 ml/min", "No pregnancy or breast-feeding", "Serum ALT < 2.0 LSN", "The ER, PR and HER2 status is required.", "- LVEF (MUGA/Echo WNL)", "No beginning > 2 neuropathy", "Urine: creataemia rate < 1.0", "HER2-negative - ratio IHC 0-1+ or FISH < 2.0", "Hemoglobin > 9 gm/dl", "(a FISH test is required for all HER2 2-3+ tumours by IHC)", "- Exclusion criteria:", "No histologically documented adenocarcinoma of the breast", "No. ANC > 1000 cells", "Women; age < 18", "- Zubrod PS > 0-1", "\u2014 Blisters < 100 000", "Stage IV typology", "Total Bilirubin > 1.5 LSN", "Metastatic diseases", "Serum creatinine > 1.5 gm/dl", "- Pre-systemic treatment of breast cancer or Creat Cl > 30 ml/min", "Pregnancy or lactation", "Serum ALT > 2.0 Initial NSL > 2 Neuropathy", "urinary proteins: creatation rate > 1.0", "HER2 positive", "Hemoglobin < 9 gm/dl"], "Results": ["Performance measures:", "Complete pathological response rate to surgery", "[Unspecified]", "Time limit: surgery about 5 months after initial treatment", "Results 1:", "Title of the arm/group : Cohort 1", "Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes week x 12 weeks with Carboplatin at AUC 6 over 30 minutes IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2 weeks x 4 cycles Avastin 10 mg/kg IV over 30-60 minutes q2 weeks x 34 weeks", "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes x 12 weeks with carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 (in Cohort 2, omit the dose of Avastin over week 10)", "Total number of participants analysed: 28", "Type of measurement: Number", "Unit of measurement: participants 16", "Results 2:", "Title of the arm/group: Cohort 2", "Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 (in Cohort 2, omit the Avastin dose over week 10) Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2 weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2 weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2 weeks x 42 weeks", "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes x 12 weeks with carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4.7 and 10 (in Cohort 2, omit the dose of Avastin over week 10)", "Total number of participants analysed: 27", "Type of measurement: Number", "Unit of measurement: participants 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/28 (17.86%)", "Gr 3 Nausea, gr 3 vomiting 1/28 (3.57%)", "Gr 3 nausea, gr 2 infection with NCA noraml, gr 2 HGB, gr 1 glucose 1/28 (3.57%)", "Gr 2 Non-cardiac chest pain, gr 2 anaemia 1/28 (3.57%)", "(cellulitis and pain in buttock infection - RT), gr 1 epistaxis 1/28 (3.57%)", "Adverse Events 2:", "Total: 8/27 (29.63%)", "Gr 3 Nausea, gr 3 vomiting 0/27 (0.00 %)", "Gr 3 nausea, gr 2 infection with NCP of noraml, gr 2 HGB, gr 1 glucose 0/27 (0.00 %)", "Gr 2 Non-cardiac chest pain, gr 2 anaemia 0/27 (0.00 %)", "(cellulitis and pain in buttock infection - RT), gr 1 epistaxis 0/27 (0.00 %)"]}